Literature DB >> 22818872

Cell models for McArdle disease and aminoglycoside-induced read-through of a premature termination codon.

Kathryn E Birch1, Ros M Quinlivan, Glenn E Morris.   

Abstract

McArdle disease results from mutations in the gene encoding muscle glycogen phosphorylase (PYGM) protein and the two most common mutations are a premature termination codon (R50X) and a missense mutation (G205S). Myoblasts from patients cannot be used to create a cell model of McArdle disease because even normal myoblasts produce little or no PYGM protein in cell culture. We therefore created cell models by expressing wild-type or mutant (R50X or G205S) PYGM from cDNA integrated into the genome of Chinese hamster ovary cells. These cell lines enable the study of McArdle mutations in the absence of nonsense-mediated decay of mRNA transcripts. Although all cell lines produced stable mRNA, only wild-type produced detectable PYGM protein. Our data suggest that the G205S mutation affects PYGM by causing misfolding and accelerated protein turnover. Using the N-terminal region of PYGM containing the R50X mutation fused to green fluorescent protein, we were able to demonstrate both small amounts of truncated protein production and read-through of the R50X premature termination codon induced by the aminoglycoside, G418.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22818872     DOI: 10.1016/j.nmd.2012.06.348

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  7 in total

1.  The pathogenomics of McArdle disease--genes, enzymes, models, and therapeutic implications.

Authors:  Gisela Nogales-Gadea; Alfredo Santalla; Astrid Brull; Noemi de Luna; Alejandro Lucia; Tomàs Pinós
Journal:  J Inherit Metab Dis       Date:  2014-07-23       Impact factor: 4.982

2.  Clinical utility gene card for McArdle disease.

Authors:  Rhonda L Taylor; Mark Davis; Emma Turner; Astrid Brull; Tomás Pinos; Macarena Cabrera; Kristen J Nowak
Journal:  Eur J Hum Genet       Date:  2018-01-25       Impact factor: 4.246

3.  Targeted Therapies for Metabolic Myopathies Related to Glycogen Storage and Lipid Metabolism: a Systematic Review and Steps Towards a 'Treatabolome'.

Authors:  A Manta; S Spendiff; H Lochmüller; R Thompson
Journal:  J Neuromuscul Dis       Date:  2021

4.  Determining the prevalence of McArdle disease from gene frequency by analysis of next-generation sequencing data.

Authors:  Mauricio De Castro; Jennifer Johnston; Leslie Biesecker
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

Review 5.  McArdle Disease: New Insights into Its Underlying Molecular Mechanisms.

Authors:  Francisco Llavero; Alazne Arrazola Sastre; Miriam Luque Montoro; Patricia Gálvez; Hadriano M Lacerda; Luis A Parada; José Luis Zugaza
Journal:  Int J Mol Sci       Date:  2019-11-25       Impact factor: 5.923

6.  Absence of p.R50X Pygm read-through in McArdle disease cellular models.

Authors:  Guillermo Tarrasó; Alberto Real-Martinez; Marta Parés; Lídia Romero-Cortadellas; Laura Puigros; Laura Moya; Noemí de Luna; Astrid Brull; Miguel Angel Martín; Joaquin Arenas; Alejandro Lucia; Antoni L Andreu; Jordi Barquinero; John Vissing; Thomas O Krag; Tomàs Pinós
Journal:  Dis Model Mech       Date:  2020-01-13       Impact factor: 5.758

Review 7.  Preclinical Research in McArdle Disease: A Review of Research Models and Therapeutic Strategies.

Authors:  Mónica Villarreal-Salazar; Astrid Brull; Gisela Nogales-Gadea; Antoni L Andreu; Miguel A Martín; Joaquín Arenas; Alfredo Santalla; Alejandro Lucia; John Vissing; Thomas O Krag; Tomàs Pinós
Journal:  Genes (Basel)       Date:  2021-12-28       Impact factor: 4.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.